...
首页> 外文期刊>Catheterization and cardiovascular interventions: Official journal of the Society for Cardiac Angiography & Interventions >The first transapical transcatheter aortic valve‐in‐valve implantation using the J J ‐valve system into a failed biophysio aortic prosthesis in a patient with high risk of coronary obstruction
【24h】

The first transapical transcatheter aortic valve‐in‐valve implantation using the J J ‐valve system into a failed biophysio aortic prosthesis in a patient with high risk of coronary obstruction

机译:第一次通过J j -valve系统进入具有高风险冠状动脉梗阻的患者的生物血症假体的失败的生物发电机术

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract We report the first successful valve‐in‐valve (ViV) implantation into a failed Edwards Biophysio surgical prosthesis (Edwards Lifesciences, Irvine, CA) and also the first use of the J‐Valve system (Jie Cheng Medical Technologies, Suzhou, China) in a ViV configuration. A 77‐year old male had symptomatic severe aortic stenosis secondary to failure of a 25 mm Biophysio bioprosthetic valve implanted 11 years previously, along with concomitant coronary artery bypass grafting. Transthoracic echocardiography (TTE) revealed calcified leaflets, a mean aortic gradient of 50 mm Hg, and an estimated valve area of 0.9 cm 2 with no aortic insufficiency. The patient had low coronary ostial height with the right coronary artery arising only 8.5 mm from the valve annulus and the left main coronary artery arising only 9.4 mm from the valve annulus. Risk of coronary ostial obstruction was especially concerning in context of both the patient's extremely low coronary ostial height and the unique structure of the Biophysio valve. Under general anesthesia, transapical transcatheter aortic ViV implantation with a 25 mm J‐Valve was performed in a hybrid operating room. The J‐Valve prosthesis was deployed in the 25 mm Biophysio surgical valve without difficulty or complications. There were no intraoperative or postoperative complications. The patient was discharged home after 3 days. TTE at 1 year showed a mean aortic valve gradient of 14 mm Hg, and no aortic insufficiency. This case demonstrated that J‐Valve implantation may be a new option for patients at high risk for coronary obstruction.
机译:摘要我们将第一个成功的阀门内(VIV)植入植入到Edwards Biophysio手术假体(Edwards Lifesciences,Irvine,CA)以及J-Valve System(Jie Cheng Medical Technologies,苏州)的首次使用)在VIV配置中。 77岁的男性具有症状严重主动脉狭窄,其25毫米生物生物生物体瓣膜植入前11年以前,以及伴随的冠状动脉旁路接枝。经脉冲超声心动图(TTE)显示钙化叶,平均主动脉梯度为50mm Hg,估计阀面积为0.9cm 2,没有主动脉的不足。患者具有低冠状动脉的骨高度,右冠状动脉距离阀环仅为8.5毫米,左主冠状动脉距离阀环仅为9.4毫米。冠状动脉溶扰性障碍的风险特别涉及患者极低的冠状动脉骨质高度和生物用阀的独特结构的背景下。在全身麻醉下,在混合手术室中进行与25mm J-valave的分类经触控管主动脉主动脉VIV植入。 J-阀假体部署在25 mm Biophysio手术瓣膜中没有困难或并发症。没有术中或术后并发症。患者在3天后排出回家。 TTE在1年显示一个平均主动脉瓣梯度为14 mm Hg,没有主动脉的不足。这种情况表明,J-瓣膜注入可能是冠状动脉阻塞高风险患者的新选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号